论文部分内容阅读
目的探讨70岁以上老年非小细胞肺癌TP方化疗耐受性。方法回顾性总结55例具有明确病理学、细胞学证据的70岁以上老年非小细胞肺癌Ⅲ期、Ⅳ期患者紫衫醇联合顺铂化疗疗效及不良反应,统计中位无进展生存期(PFS)、中位总生存期(OS)。结果化疗6个周期16例,5个周期8例,4个周期10例,3个周期12例,2个周期9例。疗效CR18例、PR22例、SD12例、PD3例。PFS、OS均较文献报道延长,无与治疗相关的死亡病例;不良反应胃肠道反应9例,骨髓抑制35例。结论 70岁以上老年非小细胞肺癌TP方化疗疗效好,副作用小,有生存获益。
Objective To investigate the chemotherapy tolerance of TP in 70-year-old elderly non-small cell lung cancer. Methods A total of 55 patients with stage Ⅲ and Ⅳ of 70-year-old elderly non-small cell lung cancer with clear pathology and cytology were reviewed retrospectively. The median progression-free survival (PFS) ), Median overall survival (OS). Results 6 cycles of chemotherapy in 16 cases, 5 cycles in 8 cases, 4 cycles in 10 cases, 3 cycles in 12 cases, 2 cycles in 9 cases. CR18 cases, PR22 cases, SD12 cases, PD3 cases. PFS, OS were longer than reported in the literature, no treatment-related deaths; adverse reactions in 9 cases of gastrointestinal reactions, bone marrow suppression in 35 cases. Conclusion TP chemotherapy of elderly patients with non-small cell lung cancer over the age of 70 has good curative effect, small side effects and survival benefit.